These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 14747424)
1. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. Peng B; Dutreix C; Mehring G; Hayes MJ; Ben-Am M; Seiberling M; Pokorny R; Capdeville R; Lloyd P J Clin Pharmacol; 2004 Feb; 44(2):158-62. PubMed ID: 14747424 [TBL] [Abstract][Full Text] [Related]
2. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710 [TBL] [Abstract][Full Text] [Related]
4. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Nikolova Z; Peng B; Hubert M; Sieberling M; Keller U; Ho YY; Schran H; Capdeville R Cancer Chemother Pharmacol; 2004 May; 53(5):433-8. PubMed ID: 15132131 [TBL] [Abstract][Full Text] [Related]
5. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559 [TBL] [Abstract][Full Text] [Related]
7. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095 [TBL] [Abstract][Full Text] [Related]
8. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692 [TBL] [Abstract][Full Text] [Related]
9. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257 [TBL] [Abstract][Full Text] [Related]
10. Absolute bioavailability of quinine formulations in Nigeria. Babalola CP; Bolaji OO; Ogunbona FA; Ezeomah E Afr J Med Med Sci; 2004 Sep; 33(3):185-9. PubMed ID: 15819461 [TBL] [Abstract][Full Text] [Related]
11. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865 [TBL] [Abstract][Full Text] [Related]
12. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Smith P; Bullock JM; Booker BM; Haas CE; Berenson CS; Jusko WJ Pharmacotherapy; 2004 Nov; 24(11):1508-14. PubMed ID: 15537555 [TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of imatinib mesylate in healthy volunteers. Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. le Coutre P; Kreuzer KA; Pursche S; Bonin Mv; Leopold T; Baskaynak G; Dörken B; Ehninger G; Ottmann O; Jenke A; Bornhäuser M; Schleyer E Cancer Chemother Pharmacol; 2004 Apr; 53(4):313-23. PubMed ID: 14658008 [TBL] [Abstract][Full Text] [Related]
15. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice. Moo KS; Radhakrishnan S; Teoh M; Narayanan P; Bukhari NI; Segarra I Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819 [TBL] [Abstract][Full Text] [Related]
18. Disposition of oral azithromycin in humans. Luke DR; Foulds G Clin Pharmacol Ther; 1997 Jun; 61(6):641-8. PubMed ID: 9209246 [TBL] [Abstract][Full Text] [Related]
19. Relative bioavailability of tizanidine hydrochloride capsule formulation compared with capsule contents administered in applesauce: a single-dose, open-label, randomized, two-way, crossover study in fasted healthy adult subjects. Henney HR; Fitzpatrick A; Stewart J; Runyan JD Clin Ther; 2008 Dec; 30(12):2263-71. PubMed ID: 19167586 [TBL] [Abstract][Full Text] [Related]
20. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]